Rxsight Inc (RXST)

$48.64

+0.92

(+1.93%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $47.45
    $49.18
    $48.64
    downward going graph

    2.45%

    Downside

    Day's Volatility :3.51%

    Upside

    1.09%

    downward going graph
  • $20.66
    $66.54
    $48.64
    downward going graph

    57.52%

    Downside

    52 Weeks Volatility :68.95%

    Upside

    26.9%

    downward going graph

Returns

PeriodRxsight IncIndex (Russel 2000)
3 Months
-10.4%
0.0%
6 Months
5.27%
0.0%
1 Year
45.62%
0.0%
3 Years
198.25%
-19.2%

Highlights

Market Capitalization
2.0B
Book Value
$4.41
Earnings Per Share (EPS)
-1.24
Wall Street Target Price
71.71
Profit Margin
-44.01%
Operating Margin TTM
-36.15%
Return On Assets TTM
-15.45%
Return On Equity TTM
-28.81%
Revenue TTM
101.1M
Revenue Per Share TTM
2.83
Quarterly Revenue Growth YOY
68.7%
Gross Profit TTM
21.3M
EBITDA
-43.4M
Diluted Eps TTM
-1.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.75
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Rxsight Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 47.43%

Current $48.64
Target $71.71

Company Financials

FY19Y/Y Change
Revenue
2.2M
-
Net Income
126.2M
-
Net Profit Margin
5.6K%
-
FY20Y/Y Change
Revenue
14.7M
↑ 554.98%
Net Income
27.6M
↓ 78.15%
Net Profit Margin
187.87%
↓ 5444.44%
FY21Y/Y Change
Revenue
22.6M
↑ 53.92%
Net Income
-48.7M
↓ 276.57%
Net Profit Margin
-215.5%
↓ 403.37%
FY22Y/Y Change
Revenue
49.0M
↑ 116.9%
Net Income
-66.8M
↑ 37.11%
Net Profit Margin
-136.22%
↑ 79.28%
FY23Y/Y Change
Revenue
89.1M
↑ 81.77%
Net Income
-48.6M
↓ 27.19%
Net Profit Margin
-54.57%
↑ 81.65%
Q4 FY22Q/Q Change
Revenue
16.1M
↑ 27.53%
Net Income
-15.6M
↓ 11.7%
Net Profit Margin
-97.03%
↑ 43.1%
Q1 FY23Q/Q Change
Revenue
17.5M
↑ 8.71%
Net Income
-14.8M
↓ 4.97%
Net Profit Margin
-84.82%
↑ 12.21%
Q2 FY23Q/Q Change
Revenue
20.8M
↑ 18.99%
Net Income
-13.8M
↓ 6.94%
Net Profit Margin
-66.33%
↑ 18.49%
Q3 FY23Q/Q Change
Revenue
30.7M
↑ 47.37%
Net Income
-12.4M
↓ 10.06%
Net Profit Margin
-40.48%
↑ 25.85%
Q4 FY23Q/Q Change
Revenue
28.6M
↓ 6.81%
Net Income
-9.2M
↓ 26.08%
Net Profit Margin
-32.11%
↑ 8.37%
Q1 FY24Q/Q Change
Revenue
29.5M
↑ 3.26%
Net Income
-9.1M
↓ 0.84%
Net Profit Margin
-30.83%
↑ 1.28%
FY19Y/Y Change
Total Assets
110.4M
-
Total Liabilities
415.0M
-
FY20Y/Y Change
Total Assets
100.7M
↓ 8.83%
Total Liabilities
398.2M
↓ 4.06%
FY21Y/Y Change
Total Assets
192.7M
↑ 91.43%
Total Liabilities
54.5M
↓ 86.32%
FY22Y/Y Change
Total Assets
150.2M
↓ 22.08%
Total Liabilities
60.3M
↑ 10.62%
FY23Y/Y Change
Total Assets
182.6M
↑ 21.57%
Total Liabilities
22.2M
↓ 63.18%
Q4 FY22Q/Q Change
Total Assets
150.2M
↓ 3.56%
Total Liabilities
60.3M
↑ 0.86%
Q1 FY23Q/Q Change
Total Assets
202.5M
↑ 34.87%
Total Liabilities
57.5M
↓ 4.55%
Q2 FY23Q/Q Change
Total Assets
195.3M
↓ 3.59%
Total Liabilities
38.1M
↓ 33.81%
Q3 FY23Q/Q Change
Total Assets
181.9M
↓ 6.87%
Total Liabilities
20.4M
↓ 46.49%
Q4 FY23Q/Q Change
Total Assets
182.6M
↑ 0.38%
Total Liabilities
22.2M
↑ 8.92%
Q1 FY24Q/Q Change
Total Assets
183.2M
↑ 0.34%
Total Liabilities
19.2M
↓ 13.3%
FY19Y/Y Change
Operating Cash Flow
-40.6M
-
Investing Cash Flow
-5.9M
-
Financing Cash Flow
1.3M
-
FY20Y/Y Change
Operating Cash Flow
-35.2M
↓ 13.33%
Investing Cash Flow
15.6M
↓ 365.6%
Financing Cash Flow
25.2M
↑ 1797.52%
FY21Y/Y Change
Operating Cash Flow
-44.7M
↑ 27.0%
Investing Cash Flow
-81.9M
↓ 625.35%
Financing Cash Flow
137.3M
↑ 444.21%
FY22Y/Y Change
Operating Cash Flow
-58.9M
↑ 31.63%
Investing Cash Flow
40.0M
↓ 148.77%
Financing Cash Flow
6.3M
↓ 95.39%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.9M
↓ 8.78%
Investing Cash Flow
10.4M
↑ 1758.04%
Financing Cash Flow
6.3M
↓ 1486.15%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.8M
↑ 28.22%
Investing Cash Flow
-48.4M
↓ 564.82%
Financing Cash Flow
65.3M
↑ 935.44%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.5M
↓ 57.52%
Investing Cash Flow
4.4M
↓ 109.09%
Financing Cash Flow
891.0K
↓ 98.64%

Technicals Summary

Sell

Neutral

Buy

Rxsight Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rxsight Inc
Rxsight Inc
-14.95%
5.27%
45.62%
198.25%
198.25%
Stryker Corporation
Stryker Corporation
-1.55%
7.98%
13.65%
32.02%
65.15%
Boston Scientific Corp.
Boston Scientific Corp.
1.97%
28.95%
47.67%
84.27%
83.02%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.74%
22.98%
-1.79%
-14.43%
43.0%
Abbott Laboratories
Abbott Laboratories
0.74%
-8.39%
-2.6%
-10.66%
24.35%
Medtronic Plc
Medtronic Plc
-2.5%
-9.93%
-10.1%
-37.82%
-21.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rxsight Inc
Rxsight Inc
NA
NA
NA
-0.75
-0.29
-0.15
NA
4.41
Stryker Corporation
Stryker Corporation
38.74
38.74
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.8
64.8
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
40.02
40.02
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.2
32.2
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.92
27.92
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rxsight Inc
Rxsight Inc
Buy
$2.0B
198.25%
NA
-44.01%
Stryker Corporation
Stryker Corporation
Buy
$129.3B
65.15%
38.74
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$113.4B
83.02%
64.8
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$56.0B
43.0%
40.02
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.3B
24.35%
32.2
13.96%
Medtronic Plc
Medtronic Plc
Buy
$98.8B
-21.91%
27.92
11.36%

Insights on Rxsight Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 28.58M → 29.51M (in $), with an average increase of 3.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 7 quarters, -17.67M → -9.1M (in $), with an average increase of 12.2% per quarter

Institutional Holdings

  • RA Capital Management, LLC

    8.77%
  • BlackRock Inc

    5.37%
  • Artisan Partners Limited Partnership

    4.83%
  • Lord, Abbett & Co LLC

    4.52%
  • Vanguard Group Inc

    3.88%
  • FMR Inc

    3.36%

Company Information

calhoun vision is the world leader in adjustable intraocular lens technology. the company's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted in the eye. this offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient. calhoun vision's light adjustable lens technology is an investigational device in the united states and requires fda approval before it can be marketed commercially. the company has completed phases i and ii of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled.

Organization
Rxsight Inc
Employees
374
CEO
Dr. Ronald M. Kurtz M.D.
Industry
Miscellaneous

FAQs